American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders4thText Revision (DSM-IV-TR)Washington, DC: American Psychiatric Association, 2000.
2.
BiedermanJ, MelmedRD, PatelA, McBurnettR, KonowJ, LyneA, SchererN. SPD503 Study Group. A randomized, double blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics, 121:E73–E84. 2008a.
3.
BiedermanJ, MelmedRD, PatelA, McBurnettK, DonahueJ, LyneA. Long term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr, 13:1047–1055. 2008b.
4.
GazzolaC. The effect of the alpha 2-adrenoceptor agonist, guanfacin, on energy expenditure, intake and deposition in rats. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol, 112:29–34. 1995.
NaranjoC, BustoU, SellersE, SandorP, RobertsE, JanecekE, DomecqC, GreenblattDJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther, 30:239–245. 1981.
7.
OswalA, YeoG. Leptin and the control of body weight: A review of its diverse central targets, signaling mechanisms, and role in the pathogenesis of obesity. Obesity, 18:221–229. 2010.
8.
SalleeF, LyneA, WigalT, McGoughJ. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol, 19:215–226. 2009a.
9.
SalleeF, McGoughJ, WigalT, DonahueJ, LyneA, BiedermanJ. SPD503 Study Group. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: A placebo-controlled trial. J Am Acad Child Adolesc Psychiatry, 48:155–165. 2009b.
10.
SillenceM, TudorG, MatthewsM, LindsayD. Effects of the alpha 2-adrenoceptor agonist guanfacine on growth and thermogenesis in mice. J Anim Sci, 70:3429–3434. 1992.
